BR112017002209A2 - method and kit for detecting a dengue virus infection - Google Patents

method and kit for detecting a dengue virus infection

Info

Publication number
BR112017002209A2
BR112017002209A2 BR112017002209A BR112017002209A BR112017002209A2 BR 112017002209 A2 BR112017002209 A2 BR 112017002209A2 BR 112017002209 A BR112017002209 A BR 112017002209A BR 112017002209 A BR112017002209 A BR 112017002209A BR 112017002209 A2 BR112017002209 A2 BR 112017002209A2
Authority
BR
Brazil
Prior art keywords
dengue
dengue virus
antigens
antibodies
virus
Prior art date
Application number
BR112017002209A
Other languages
Portuguese (pt)
Inventor
Kumar Sil Bijon
Sin Ivy Teoh Lay
Mya Soe Mya
Hu Weiping
Original Assignee
Mp Biomedicals Asia Pacific Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mp Biomedicals Asia Pacific Pte Ltd filed Critical Mp Biomedicals Asia Pacific Pte Ltd
Publication of BR112017002209A2 publication Critical patent/BR112017002209A2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Abstract

a presente invenção fornece ?ponto de cuidado de teste? (poct) com base na dengue multiplex para a detecção simultânea de dois componentes imunológicos constrastantes (antígenos e anticorpos) em um indivíduo que teve exposição a um vírus da dengue ou relativo imunológico do mesmo ou que desenvolveu algum nível de imunidade contra um antígeno do vírus da dengue e/ou antígenos sintetizados na célula infectada pelo vírus da dengue no corpo hospedeiro. o método é prognosticado na detecção de duas classes diferentes de parceiros de ligação: anticorpos específicos (iga, igm & igg) e antígenos: não estrutural - 1 (ns1) e estrutural (envelope). esta única combinação de cinco biomarcadores superará o desafio corrente de diagnóstico de dengue onde a detecção da infecção secundária pela dengue está sempre em questão em questão. o poct compreende contatar uma amostra biológica do indivíduo com uma mistura de componentes imunogênicos específicos do vírus da dengue; e determinar a presença de um complexo que forma entre um parceiro de ligação na amostra biológica e um componente imunogênico específico do vírus da dengue; e caracterizando os parceiros de ligação no complexo com um parceiro de antiligação: anticorpos e antígeno conjugados com colóide de ouro usando a tecnologia de fluxo reverso de câmara dupla.The present invention provides? test point of care? (poct) based on dengue multiplex for the simultaneous detection of two contrasting immune components (antigens and antibodies) in an individual who has had exposure to a dengue or relative immune dengue virus or who has developed some level of immunity against a virus antigen dengue fever and / or antigens synthesized in the cell infected by the dengue virus in the host body. The method is predicted to detect two different classes of binding partners: specific antibodies (iga, igm & igg) and antigens: nonstructural - 1 (ns1) and structural (envelope). This unique combination of five biomarkers will overcome the current challenge of dengue diagnosis where detecting secondary dengue infection is always in question. poct comprises contacting a biological sample from the subject with a mixture of dengue virus specific immunogenic components; and determining the presence of a complex that forms between a binding partner in the biological sample and a dengue virus specific immunogenic component; and characterizing the binding partners in the complex with an anti-binding partner: gold colloid conjugated antibodies and antigen using dual chamber reverse flow technology.

BR112017002209A 2014-08-01 2015-08-03 method and kit for detecting a dengue virus infection BR112017002209A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201404571PA SG10201404571PA (en) 2014-08-01 2014-08-01 Method and kit for detecting a dengue virus infection
PCT/SG2015/050248 WO2016022071A1 (en) 2014-08-01 2015-08-03 Method and kit for detecting a dengue virus infection

Publications (1)

Publication Number Publication Date
BR112017002209A2 true BR112017002209A2 (en) 2018-08-14

Family

ID=55264219

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002209A BR112017002209A2 (en) 2014-08-01 2015-08-03 method and kit for detecting a dengue virus infection

Country Status (3)

Country Link
BR (1) BR112017002209A2 (en)
SG (2) SG10201404571PA (en)
WO (1) WO2016022071A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017144174A1 (en) * 2016-02-22 2017-08-31 Euroimmun Medizinische Labordiagnostika Ag An immunoassay for the diagnosis of viral infections
US11022611B2 (en) 2016-05-03 2021-06-01 Nirmidas Biotech, Inc. Methods and systems for diagnosis and treatment of viral infections
AU2017277065A1 (en) 2016-06-06 2019-01-17 Medizinische Universität Wien Method for the detection of an IgM antibody specific for a flavivirus in a sample
EP3312610A1 (en) * 2016-10-19 2018-04-25 Mikrogen GmbH Verfahren zur immunologischen diagnose einer probe mit einer potentiellen infektion eines arbovirus und hierfür geeignete testkits
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
WO2018081754A1 (en) * 2016-10-29 2018-05-03 University Of Miami Anti-zika virus antibodies
GB201719592D0 (en) * 2017-11-24 2018-01-10 Tedder Richard Flavivirus diagnostic assay
KR102238183B1 (en) * 2018-05-04 2021-04-12 가톨릭대학교 산학협력단 Recombinant pangenotype complex NS1 antigen pool of dengue virus and endemic flaviviruses designed by gene synthesis
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
JP2022505934A (en) * 2018-10-24 2022-01-14 オラシュアテクノロジーズ， インコーポレイテッド Lateral flow assay for differential isotype detection
CN111273001A (en) * 2020-02-12 2020-06-12 北京大弘生物技术有限公司 System for rapidly detecting new coronavirus 2019-nCoV in blood sample and preparation method thereof
WO2021202992A2 (en) * 2020-04-03 2021-10-07 Lawrence Loomis Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19
US20230204574A1 (en) * 2020-04-24 2023-06-29 Massachusetts Institute Of Technology Rapid, point of care detection of neutralizing antibodies against a virus
WO2022036337A1 (en) * 2020-08-13 2022-02-17 Diaclone Llc Compositions and methods for recombinant polypeptide mimicking sars-cov-2 nucleocapsid protein (np)
WO2022074111A1 (en) * 2020-10-07 2022-04-14 Sanofi Pasteur Improved diagnostic tests

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2767324B1 (en) * 1997-08-14 2001-04-06 Pasteur Institut USE OF RECOMBINANT ENVELOPE PROTEINS FOR THE DIAGNOSIS OF DENGUE VIRUS
SG157244A1 (en) * 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
CN102393454A (en) * 2011-08-24 2012-03-28 中国检验检疫科学研究院 Colloidal gold test strip for detecting dengue virus antibody and preparation method and application thereof

Also Published As

Publication number Publication date
SG11201700786TA (en) 2017-02-27
SG10201404571PA (en) 2016-03-30
WO2016022071A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
BR112017002209A2 (en) method and kit for detecting a dengue virus infection
BR112018016337A2 (en) monoclonal antibodies to antidengue virus protein ns1
MX2020009021A (en) Assays for detecting the presence or amount of an anti-drug antibody.
MX362075B (en) Hcv antigen-antibody combination assay and methods and compositions for use therein.
BR112016007106A2 (en) improved pregnancy test device and method
BR112014027465A8 (en) in vitro test method, detection kit, kit uses, in vitro diagnostic method and method for making a kit
SG135990A1 (en) Competitive enzyme linked immunosorbent assay (c-elisa) for the detection of a flavivirus specific antibody
SG11201810029PA (en) Immunochromatography Analysis Device for Detecting Zika Virus
BR112015026246A2 (en) blood collection and blood separation transfer device and testing system
BR112016014010A2 (en) methods for detecting antibodies to wild-type classical swine fever virus (csfv), to differentiate between wild-type csfv-infected animals and animals that have been vaccinated against csfv, and to control a wild-type csfv infection, diagnostic test kit, and, use of a carrier
BR112016009460A8 (en) method to detect the presence of neutralizing antibodies, and, kit
BR112015008036A2 (en) isolated peptide population, method for detecting antibody in a sample, method for diagnosing monocytic and / or granulocytic erlichiosis, and kit
BR112016007037A2 (en) method for detecting pancreatic cancer, monoclonal antibody and kit
CO6311040A2 (en) CARE TEST POINT FOR DETECTION OF A SUBJECT EXPOSED TO THE DENGUE VIRUS OR THAT HAS REACHED A CERTAIN LEVEL OF IMMUNITY AGAINST AN ANTIGEN OF THE DENGUE VIRUS
HRP20171623T1 (en) Improved vaccine diagnostics
BR112016017926A2 (en) Assay for human periostin
EA201400571A1 (en) SPECIFIC TO TRANSRESVEROTROL ANTIBODIES AND THEIR APPLICATION
BR112016021714A2 (en) immunoassay and antibodies for the detection of chromogranin at
WO2018172337A8 (en) Immunoassay for detecting zika virus infection
BR112017009029A2 (en) anti-hcv antibody detection assays of an individual using ns3 capture peptides
EA201991843A1 (en) METHOD OF IMMUNOLOGICAL DETERMINATION OF SPECIFIC ANTIBODIES TO VIRUS ANTIGENES OF THE POXVIRUS FAMILY
BR112017009309A2 (en) test device for measuring the amount of analyte in a fluid sample, method for making a test device for measuring the amount of analyte in a fluid sample, and method of using a test device
BR112017004810A2 (en) immunoassay
WO2014126487A3 (en) Diagnosis and detection of dengue virus infection using chicken egg antibodies
MX2023007633A (en) African swine fever diva immunoassay.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]